CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals
- 30 March 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 14 (4), 413-420
- https://doi.org/10.1038/nm1741
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- HLA‐Bw4Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral TherapyClinical Infectious Diseases, 2008
- Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter CohortPLOS ONE, 2006
- Lack of Mucosal Immune Reconstitution during Prolonged Treatment of Acute and Early HIV-1 InfectionPLoS Medicine, 2006
- Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological responseAIDS, 2006
- Influence of Host Genetic Variation on Susceptibility to HIV Type 1 InfectionThe Journal of Infectious Diseases, 2005
- The Case for Earlier Treatment of HIV InfectionClinical Infectious Diseases, 2004
- T Cell Dynamics in HIV-1 InfectionAnnual Review of Immunology, 2003
- Concordance between the CC Chemokine Receptor 5 Genetic Determinants That Alter Risks of Transmission and Disease Progression in Children Exposed Perinatally to Human Immunodeficiency VirusThe Journal of Infectious Diseases, 2001
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infectionAIDS, 1998